Journal article · 2025 · Open access
ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE
Annals of the Rheumatic Diseases, 84, 1510–1511 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.06.870
In brief
“ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE” is a 2025 journal article by L. Bucci and 16 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 4 citations as of 20 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.
- Citations
- 4
- Most cited in
- 2025 (2)
- Authors
- 17
Abstract
Background: T cell engagers (TCEs) redirect T cells for targeted cytotoxicity and are emerging as promising therapeutic strategy to deplete B cells in autoimmune disease (AID). Recent data demonstrate the safety and short-term clinical efficacy of CD19 and BCMA targeted T cell engagers in various AID, yet patient numbers and length of follow-up remain limited [1–3]. Objectives: Here we present a current analysis of the safety and clinical efficacy from 24 patients with various autoimmune diseases treated with TCEs. Methods: A total of 24 patients with multi-drug-resistant autoimmune diseases (AIDs) received TCE therapy as inpatients in our center in a compassionate use program. 14 patients with rheumatoid arthritis (RA) were treated with the CD19xCD3 TCE blinatumomab, while 10 patients (systemic sclerosis (SSc), N=3, idiopathic inflammatory myositis (IIM) N=2, IgG4-related disease (IgG4-RD) N=2, primary Sjoegren's-Syndrome (SjS) N=1, Graves disease (GD) N=1,) and RA N=1) were treated with the plasma cells targeting BCMAxCD3 TCE teclistamab. RA patients received 2–3 cycles of low dose blinatumomab therapy as 96-hour continuous intravenous infusion. The cumulative dose of Blinatumomab ranged from 77 µg to 189 µg. Teclistamab was administered as subcutaneous injection using the standard step-up dose (d1: 0.06 mg/Kg; d3: 0.3 mg/Kg; d5: 1.5 mg/Kg). A maintenance dose of 1.5 mg/Kg was administered after 4 weeks. Adverse events such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and immune effector cell–associated hematotoxicity syndrome (ICAHTS) were recorded and monitored after the therapy. Clinical efficacy was assessed using the disease-specific combined scores (DAS 28; ESSDAI; mRSS; CDASI, MMT8) and the visual analog scale (VAS). Results: Treatment with both oth TCEs was well tolerated. No cases of ICANS and ICAHTS were recorded. Low-grade CRS (grade 1-2) was observed in 3 of 14 patients treated with blinatumomab and in 8 of 10 patients treated with teclistamab. Mild infections occurred in 4 of 14 of patients treated with blinatumomab and in all patients treated with Teclistamab. Three severe infections were observed after teclistamab: one viral gastroenteritis with dehydration, which resolved upon symptomatic management and two bacterial infections ( Clostridium difficile infection and urinary tract infection), which resolved upon intravenous antibiotic treatment. All patients showed initial clinical and serological response. In RA patients treated with blinatumomab, the median number of tender joints decreased from 9 [range: 2–39] to 1.5 [range: 0–5] and the number of swollen joints decreased from 8 [range: 1–35] to 1 [range: 0–6] VAS improved from 70 [range: 40–90] to 20 [range: 0–60]. DAS28-CRP decreased from 5.13 to 2.6, leading to DAS28-CRP remission in 9/14…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Bucci, L., Boeltz, S., Hagen, M., Nöthling, D.-M., Rothe, T., Tur, C., Wirsching, A., Auth, J., Wacker, J., Eckstein, M., Alivernini, S., Bözec, A., Bergmann, C., D’Agostino, M. A., Raimondo, M. G., Schett, G. A., & Grieshaber‐Bouyer, R. (2025). ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE. Annals of the Rheumatic Diseases, 84, 1510–1511. https://doi.org/10.1016/j.ard.2025.06.870
MLA 9
Bucci, L., et al. “ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE.” Annals of the Rheumatic Diseases, vol. 84, 2025, pp. 1510–1511. https://doi.org/10.1016/j.ard.2025.06.870.
Chicago
Bucci, L., Sebastian Boeltz, Melanie Hagen, Danae-Mona Nöthling, Tobias Rothe, Carlo Tur, Andreas Wirsching, et al. 2025. “ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE.” Annals of the Rheumatic Diseases 84: 1510–1511. https://doi.org/10.1016/j.ard.2025.06.870.
Harvard
Bucci, L. et al. (2025) ‘ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE’, Annals of the Rheumatic Diseases, 84, pp. 1510–1511. doi:10.1016/j.ard.2025.06.870.
IEEE
L. Bucci et al., “ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE,” Annals of the Rheumatic Diseases, vol. 84, pp. 1510–1511, 2025, doi: 10.1016/j.ard.2025.06.870.
BibTeX
@article{bucci2025safety,
title = {{ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE}},
author = {Bucci, L. and Boeltz, Sebastian and Hagen, Melanie and Nöthling, Danae-Mona and Rothe, Tobias and Tur, Carlo and Wirsching, Andreas and Auth, J. and Wacker, Jochen and Eckstein, Markus and Alivernini, Stefano and Bözec, Aline and Bergmann, Christina and D’Agostino, Maria Antonietta and Raimondo, Maria Gabriella and Schett, Georg Andreas and Grieshaber‐Bouyer, Ricardo},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
pages = {1510--1511},
doi = {10.1016/j.ard.2025.06.870},
url = {https://doi.org/10.1016/j.ard.2025.06.870}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- T-cell engagers
- refractory autoimmune disease
- blinatumomab
- teclistamab
- CD19
- BCMA
- rheumatoid arthritis
- systemic sclerosis
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Bucci, L., Boeltz, S., Hagen, M., Nöthling, D.-M., Rothe, T., Tur, C., Wirsching, A., Auth, J., Wacker, J., Eckstein, M., Alivernini, S., Bözec, A., Bergmann, C., D’Agostino, M. A., Raimondo, M. G., Schett, G. A., & Grieshaber‐Bouyer, R. (2025). ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE. Annals of the Rheumatic Diseases, 84, 1510–1511. https://doi.org/10.1016/j.ard.2025.06.870
How many times has this paper been cited?
4 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.
Who wrote this paper?
L. Bucci, Sebastian Boeltz, Melanie Hagen, Danae-Mona Nöthling, Tobias Rothe, Carlo Tur, Andreas Wirsching, J. Auth, Jochen Wacker, Markus Eckstein, Stefano Alivernini, Aline Bözec and 5 more.
What is the DOI of this paper?
10.1016/j.ard.2025.06.870, permanently at https://doi.org/10.1016/j.ard.2025.06.870. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.